Information Center

  • Move News
  • Move FAQ
  • inquiry

News News

Samyang Biopharmaceuticals Corporation Hosted Webinar for Oncologists in Southeast Asia Scrap Facebook Scrap Twitter Print
Writer administrator Hits 3469 2021.03.22

- Shared the latest trends in anticancer therapy using “Genexol PM” with 200 healthcare professionals from Korea, Vietnam, Malaysia, and Thailand
- Exporting drug substances and drug products to 50 companies in 20 countries including advanced ones such as Germany and Japan
- “We will continue to host online webinars to share the latest insights on Genexol PM and various anticancer drugs”

▲ Around 200 healthcare professionals attended a webinar hosted by Samyang Biopharmaceuticals Corporation.


Samyang Biopharmaceuticals Corporation shared the latest trends in anticancer therapy based on Genexol PM Inj. with oncologists in Southeast Asia. Genexol PM is an anticancer drug that has improved the shortcoming of Genexol Inj. (active ingredient: paclitaxel) for breast cancer, ovarian cancer, and lung cancer.


Samyang Biopharmaceuticals Corporation (CEO: President Eom Tae-ung) announced on March 15 that the company hosted a webinar under the title of “Breast Cancer Patient Treatment with Genexol PM (export name for Southeast Asia: Paxus PM)” participated by around 200 healthcare professionals from Korea, Vietnam, the Philippines, Malaysia, and Thailand.


In this webinar, Prof. Kim Sung-bae from the Department of Oncology, Asan Medical Center and Dr. Mohamed Ibrahim A. Wahid from Beacon Hospital, Malaysia, gave presentations. Professor Kim, who participated in a Phase III trial of breast cancer, shared the effect and latest clinical cases of Genexol PM Inj. in breast cancer patients.


Genexol PM Inj., to which Samyang Biopharmaceuticals Corporation’s drug delivery system was applied to overcome the shortcoming of paclitaxel which hardly dissolves in water, was launched in 2006 in Korea. While traditional paclitaxel injections have had a limitation in dose due to toxicity/side effects associated with solubilizer, Genexol PM do not include any solubilizer, thus enabling the high-dose administration.


Southeast Asian healthcare professionals attending the webinar asked breast cancer treatment experiences using Genexol PM and showed great interest in Genexol PM.


Samyang Biopharmaceuticals Corporation succeeded in mass production of paclitaxel from plant cell culture for the first time in the world in 1995. After it started exporting drug substances in 2002, the company also began to export Genexol Inj. drug products since 2003. Currently, Samyang Biopharmaceuticals Corporation is exporting various anticancer drug substances and products to 50 companies in about 20 countries around the world including advanced ones such as Germany and Japan. 


In partnership with “Kalbe International,” Samyang Biopharmaceuticals Corporation exports Genexol and Genexol PM under the name of Paxus and Paxus PM to Indonesia, Vietnam, the Philippines, Malaysia, and Thailand. The company will soon export them to Myanmar as well. Kalbe International is a subsidiary responsible for exporting and importing pharmaceuticals under the Kalbe Group, the largest pharmaceutical group in Indonesia.


An official from Samyang Biopharmaceuticals Corporation said, “From this webinar, we have confirmed that there was a lot of interest regarding Genexol PM among healthcare professionals abroad. Once we obtain additional clinical data including more indications and methods of administration, Genexol PM can be used in more various ways. We will continue to host online webinars to share the latest insights on Genexol PM and other anticancer treatment with healthcare professionals in Korea and abroad.”


News Previous article, News Next article, and title
이전글 Samyang Group Sudang Foundation Held the 30th Sudang Awards 2021.05.11
다음글 Samyang Group’s Yangyoung Foundation and Sudang Foundation Provide Scholarships for 2021 2021.03.03